Literature DB >> 20940397

Peptide vaccination after T-cell transfer causes massive clonal expansion, tumor eradication, and manageable cytokine storm.

Long V Ly1, Marjolein Sluijter, Mieke Versluis, Gre P M Luyten, Marianne J van Stipdonk, Sjoerd H van der Burg, Cornelis J M Melief, Martine J Jager, Thorbald van Hall.   

Abstract

Adoptive T-cell transfer (ACT) is successfully applied as a cancer treatment that is based on the activation and effector functions of tumor-specific T cells. Here, we present results from a mouse model in which ACT is combined with a long peptide-based vaccine comprising gp100 T-cell epitopes. Transferred CD8(+) T cells expanded up to 1,000-fold after peptide vaccination, leading to a 3-fold increase in white blood cell count and a very high frequency in the generation of antigen-specific memory T cells, the generation of which tended to correlate with effective antitumor responses. An enormous pool of effector T cells spread widely to different tissues, including the skin and the immune-privileged eye, where they mediate tumor eradication. Importantly, these striking T-cell dynamics occurred in immunocompetent mice without prior hematologic conditioning. Continued activation of the specific T-cell pool by vaccination led to strong T-cell-mediated cytokine storm and lethality due to multi-organ failure. However, this immunopathology could be prevented by controlling the rapid biodistribution of the peptide or by using a weakly agonistic peptide. Together, these results identify a peptide vaccination strategy that can potently accentuate effective ACT in non-lymphodepleted hosts. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20940397     DOI: 10.1158/0008-5472.CAN-10-2288

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  22 in total

1.  NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

Authors:  Nadine van Montfoort; Linda Borst; Michael J Korrer; Marjolein Sluijter; Koen A Marijt; Saskia J Santegoets; Vanessa J van Ham; Ilina Ehsan; Pornpimol Charoentong; Pascale André; Nicolai Wagtmann; Marij J P Welters; Young J Kim; Sytse J Piersma; Sjoerd H van der Burg; Thorbald van Hall
Journal:  Cell       Date:  2018-11-29       Impact factor: 41.582

Review 2.  Supportive care in patients with acute leukaemia: historical perspectives.

Authors:  Giovanna Cannas; Xavier Thomas
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

Review 3.  Biomimetic and synthetic interfaces to tune immune responses.

Authors:  Anusha Garapaty; Julie A Champion
Journal:  Biointerphases       Date:  2015-09-15       Impact factor: 2.456

4.  T-cell mediated anti-tumor immunity after photodynamic therapy: why does it not always work and how can we improve it?

Authors:  Florian Anzengruber; Pinar Avci; Lucas Freitas de Freitas; Michael R Hamblin
Journal:  Photochem Photobiol Sci       Date:  2015-06-11       Impact factor: 3.982

5.  Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.

Authors:  Christopher A Klebanoff; Luca Gattinoni; Douglas C Palmer; Pawel Muranski; Yun Ji; Christian S Hinrichs; Zachary A Borman; Sid P Kerkar; Christopher D Scott; Steven E Finkelstein; Steven A Rosenberg; Nicholas P Restifo
Journal:  Clin Cancer Res       Date:  2011-07-07       Impact factor: 12.531

Review 6.  Biomaterials for nanoparticle vaccine delivery systems.

Authors:  Preety Sahdev; Lukasz J Ochyl; James J Moon
Journal:  Pharm Res       Date:  2014-05-22       Impact factor: 4.200

Review 7.  Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.

Authors:  Cornelis J M Melief; John J O'Shea; David F Stroncek
Journal:  J Transl Med       Date:  2011-07-08       Impact factor: 5.531

Review 8.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

Review 9.  Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

Authors:  Joseph Obeid; Yinin Hu; Craig L Slingluff
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

10.  Relapse or eradication of cancer is predicted by peptide-major histocompatibility complex affinity.

Authors:  Boris Engels; Victor H Engelhard; John Sidney; Alessandro Sette; David C Binder; Rebecca B Liu; David M Kranz; Stephen C Meredith; Donald A Rowley; Hans Schreiber
Journal:  Cancer Cell       Date:  2013-04-15       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.